- Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects CNBC
- Pfizer drops plan to study twice-daily obesity pill in late-stage studies Reuters
- Disappointing trial forces Pfizer to pivot on obesity medicine plans STAT
- Rival drugmakers enter the weight loss race Investors Chronicle
Source: Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects – CNBC
